文献速递肝病

2型糖尿病患者中非酒精性脂肪性肝病的全球患病率:更新的系统综述与荟萃分析

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
PubMed 文献 · Gut · 2023-07-25

该系统综述与荟萃分析检索MEDLINE和Embase至2023年2月13日,纳入156项研究、1 832 125例患者,确定2型糖尿病患者中非酒精性脂肪性肝病患病率为65.04%、非酒精性脂肪性肝炎为31.55%,临床显著纤维化(F2-F4)为35.54%、进展期纤维化(F3-F4)为14.95%。

要点

  • 2型糖尿病患者中非酒精性脂肪性肝病汇总患病率为65.04%,非酒精性脂肪性肝炎为31.55%。
  • 合并非酒精性脂肪性肝病的2型糖尿病患者中,临床显著纤维化(F2-F4)为35.54%,进展期纤维化(F3-F4)为14.95%。
  • 研究结论认为需加大力度预防2型糖尿病以应对非酒精性脂肪性肝病负担上升。

核心结论

  • 研究确定2型糖尿病患者中非酒精性脂肪性肝病、非酒精性脂肪性肝炎和纤维化患病率均较高。
  • 需加大力度预防2型糖尿病,以应对非酒精性脂肪性肝病负担的上升。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Embase数据库自建库至2023年2月13日。
  • 纳入156项符合标准的研究,汇总分析1 832 125例患者。
  • 采用广义线性混合模型与Clopper-Pearson区间分析比例,并进行敏感性分析以探索研究间异质性。
  • 已在PROSPERO注册,注册号CRD42022360251。

主要发现

  • 2型糖尿病患者中非酒精性脂肪性肝病汇总患病率为65.04%(95%CI 61.79%至68.15%,I²=99.90%)。
  • 2型糖尿病患者中非酒精性脂肪性肝炎汇总患病率为31.55%(95%CI 17.12%至50.70%,I²=97.70%)。
  • 合并非酒精性脂肪性肝病的2型糖尿病患者中,临床显著纤维化(F2-F4)患病率为35.54%(95%CI 19.56%至55.56%,I²=100.00%)。
  • 合并非酒精性脂肪性肝病的2型糖尿病患者中,进展期纤维化(F3-F4)患病率为14.95%(95%CI 11.03%至19.95%,I²=99.00%)。

关键数值与推荐

  • 主要结局为2型糖尿病患者中非酒精性脂肪性肝病、非酒精性脂肪性肝炎和纤维化的患病率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非酒精性脂肪性肝病患病率汇总分析的异质性I²=99.90%。
  • 非酒精性脂肪性肝炎患病率汇总分析的异质性I²=97.70%。
  • 临床显著纤维化(F2-F4)患病率汇总分析的异质性I²=100.00%。
  • 进展期纤维化(F3-F4)患病率汇总分析的异质性I²=99.00%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. METHODS: MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. RESULTS: 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 patients determined that the prevalence rates of NAFLD and NASH in T2DM were 65.04% (95% CI 61.79% to 68.15%, I2=99.90%) and 31.55% (95% CI 17.12% to 50.70%, I2=97.70%), respectively. 35.54% (95% CI 19.56% to 55.56%, I2=100.00%) of individuals with T2DM with NAFLD had clinically significant fibrosis (F2-F4), while 14.95% (95% CI 11.03% to 19.95%, I2=99.00%) had advanced fibrosis (F3-F4). CONCLUSION: This study determined a high prevalence of NAFLD, NASH and fibrosis in people with T2DM. Increased efforts are required to prevent T2DM to combat the rising burden of NAFLD. PROSPERO REGISTRATION NUMBER: CRD42022360251.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023. PMID: 37491159. doi:10.1136/gutjnl-2023-330110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。